Skip to content

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals to Host Key Opinion Leader Event on S1P Modulation and Etrasimod in Autoimmune Diseases on January 29 in New York City
- Jerold Chun, M.D., Ph.D. (Sanford Burnham Prebys), and Eric Gershwin, M.D. (UC Davis Health), to Present
View HTML
Toggle Summary Arena Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 10
SAN DIEGO , Dec. 21, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, will present a corporate update at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10 , at 2:30
View HTML
Toggle Summary Arena Pharmaceuticals and Everest Medicines Enter into Development and Commercialization Partnership for Ralinepag and Etrasimod in China
Arena eligible to receive up to $224M, including upfront and milestone payments, in addition to royalties
View HTML
Toggle Summary Arena Pharmaceuticals Completes Full Enrollment in Etrasimod Phase 2 Clinical Study for Ulcerative Colitis
Data Readout Expected in Q1 2018
View HTML
Toggle Summary Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial Results
- Submitted Ralinepag FDA Meeting Request<br>- Expect to Complete Full Enrollment for Etrasimod Phase 2 Study in Ulcerative Colitis This Week<br>- Initiated Etrasimod Phase 2 Study in Primary Biliary Cholangitis
View HTML
Toggle Summary Arena Pharmaceuticals to Present at the Credit Suisse Healthcare Conference on November 8
SAN DIEGO , Oct. 31, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Kevin R. Lind , the Company's Executive Vice President and Chief Financial Officer, will present a corporate update at the 26th Annual Credit Suisse Healthcare Conference on Wednesday, November
View HTML
Toggle Summary Arena Pharmaceuticals to Release Third Quarter 2017 Financial Results and Provide Corporate Update on Tuesday, November 7
SAN DIEGO , Oct. 30, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that the Company will release its third quarter 2017 financial results and provide a corporate update on Tuesday, November 7, 2017 , after the close of the U.S.
View HTML
Toggle Summary Arena Pharmaceuticals Announces Late Breaking Presentation of Positive Phase 2 Results with Ralinepag in Patients with Pulmonary Arterial Hypertension at the American College of Chest Physicians 2017 Annual Meeting
Significant improvement in pulmonary vascular resistance (PVR) with ralinepag compared to placebo
View HTML
Toggle Summary Arena Pharmaceuticals to Present Additional Pre-Clinical Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at International Congress of the European Respiratory Society
SAN DIEGO , Sept. 6, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) will present additional detailed pre-clinical pharmacology and pharmacokinetic data on ralinepag (APD811), the Company's next-generation, oral, selective prostacyclin receptor (IP) agonist intended for the
View HTML
Toggle Summary Arena Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO , Aug. 29, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that members of its senior management team will participate in the following investor conferences in September: Liolios Gateway Conference - Presenting on Wednesday, September 6 at 10:00 a.m.
View HTML